CN103987408A - 通过药理学靶向Kv1.3钾通道治疗肥胖和肥胖相关病症 - Google Patents

通过药理学靶向Kv1.3钾通道治疗肥胖和肥胖相关病症 Download PDF

Info

Publication number
CN103987408A
CN103987408A CN201280049696.6A CN201280049696A CN103987408A CN 103987408 A CN103987408 A CN 103987408A CN 201280049696 A CN201280049696 A CN 201280049696A CN 103987408 A CN103987408 A CN 103987408A
Authority
CN
China
Prior art keywords
aeeac
chemical entity
shk toxin
linked
pmp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280049696.6A
Other languages
English (en)
Chinese (zh)
Inventor
G.K.钱迪
S.K.乌帕海亚伊
P.H.王
P.S.科西
K.L-E.马汉
S.亚多纳托
J.马克吉
R.M.米尔波卢基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
First Geordie Tower Co Ltd
CALIFORNIA SENATE
Original Assignee
First Geordie Tower Co Ltd
CALIFORNIA SENATE
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by First Geordie Tower Co Ltd, CALIFORNIA SENATE filed Critical First Geordie Tower Co Ltd
Publication of CN103987408A publication Critical patent/CN103987408A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1767—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • C07K14/43595—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates from coelenteratae, e.g. medusae
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201280049696.6A 2011-10-03 2012-10-02 通过药理学靶向Kv1.3钾通道治疗肥胖和肥胖相关病症 Pending CN103987408A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161542751P 2011-10-03 2011-10-03
US61/542,751 2011-10-03
PCT/US2012/058495 WO2013052507A1 (en) 2011-10-03 2012-10-02 TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Publications (1)

Publication Number Publication Date
CN103987408A true CN103987408A (zh) 2014-08-13

Family

ID=48044112

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280049696.6A Pending CN103987408A (zh) 2011-10-03 2012-10-02 通过药理学靶向Kv1.3钾通道治疗肥胖和肥胖相关病症

Country Status (16)

Country Link
US (2) US20150072940A1 (enExample)
EP (1) EP2763702A4 (enExample)
JP (1) JP2014531469A (enExample)
KR (1) KR20140108518A (enExample)
CN (1) CN103987408A (enExample)
AU (1) AU2012318736A1 (enExample)
BR (1) BR112014008065A2 (enExample)
CA (1) CA2850357A1 (enExample)
HK (1) HK1201048A1 (enExample)
IL (1) IL231873A0 (enExample)
IN (1) IN2014CN03333A (enExample)
MX (1) MX2014004029A (enExample)
RU (1) RU2014117558A (enExample)
SG (1) SG11201401193XA (enExample)
TW (1) TW201321403A (enExample)
WO (1) WO2013052507A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1796709A4 (en) * 2004-10-07 2009-10-28 Univ California ANALOGUES OF TOXIN SHK AND USES IN SELECTIVE INHIBITION OF KV1.3 POTASSIUM CHANNELS
CA2838474A1 (en) * 2011-06-06 2012-12-13 Kineta One, Llc Shk-based pharmaceutical compositions and methods of manufacturing and using the same
SG11201401193XA (en) 2011-10-03 2014-05-29 Univ California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS
JP7211704B2 (ja) * 2015-01-29 2023-01-24 ノヴォ ノルディスク アー／エス Ｇｌｐ－１アゴニスト及び腸溶コーティングを含む錠剤
TWI701249B (zh) 2015-03-13 2020-08-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用
TWI698438B (zh) 2015-03-13 2020-07-11 德商４Ｓｃ製藥公司 Ｋv１.３抑制劑及其醫學應用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032595A1 (en) * 2001-06-12 2003-02-13 Gary Desir Compositions and methods relating to glucose metabolism, weight control, and food intake
WO2007020286A2 (en) * 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
CN101072577A (zh) * 2004-10-07 2007-11-14 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
WO2010066840A1 (en) * 2008-12-12 2010-06-17 Solvay Pharmaceuticals B.V. SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5453270A (en) 1992-03-30 1995-09-26 Hypermetabolic Therapies, Inc. Pharmaceutical composition and method for hypermetabolic weight loss
US6077680A (en) * 1996-11-27 2000-06-20 The University Of Florida ShK toxin compositions and methods of use
AU8052798A (en) * 1997-09-17 1999-04-05 Bachem Bioscience, Inc. Polypeptide compositions that inhibit potassium channel activity and uses herefor
JP3207823B2 (ja) 1999-04-28 2001-09-10 リノール油脂株式会社 共役リノール酸を有効成分とする褐色脂肪増加剤
US6616944B2 (en) 2000-03-08 2003-09-09 Medinnova Gesellschaft Fur Medizinsche Innovationen Aus Adkademischer Forschung Mbh Self-assembling colloidal carriers for protein delivery
US7833979B2 (en) * 2005-04-22 2010-11-16 Amgen Inc. Toxin peptide therapeutic agents
SG11201401193XA (en) 2011-10-03 2014-05-29 Univ California TREATMENT OF OBESITY AND OBESITY-RELATED DISORDERS BY PHARMACOLOGICAL TARGETING OF Kv1.3 POTASSIUM CHANNELS

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030032595A1 (en) * 2001-06-12 2003-02-13 Gary Desir Compositions and methods relating to glucose metabolism, weight control, and food intake
CN101072577A (zh) * 2004-10-07 2007-11-14 加利福尼亚大学董事会 ShK毒素类似物及其在选择性抑制Kv1.3钾通道中的应用
WO2007020286A2 (en) * 2005-08-17 2007-02-22 Solvay Pharmaceuticals Gmbh Method of using potassium channel inhibiting compounds
WO2010066840A1 (en) * 2008-12-12 2010-06-17 Solvay Pharmaceuticals B.V. SPIRO AZEPANE-OXAZOLIDINONES AS Kv1.3 POTASSIUM CHANNEL BLOCKERS

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CHRISTINE BEETON 等: "Targeting Effector Memory T Cells with a Selective Peptide Inhibitor of Kv1.3 Channels for Therapy of Autoimmune Diseases", 《MOLECULAR PHARMACOLOGY》, vol. 67, no. 4, 30 April 2005 (2005-04-30), pages 1369 - 1381, XP002426710, DOI: 10.1124/mol.104.008193 *
JIANCHAO XU 等: "The voltage-gated potassium channel Kv1.3 regulates energy homeostasis and body weight", 《HUMAN MOLECULAR GENETICS》, vol. 12, no. 5, 31 March 2003 (2003-03-31), pages 551 - 559, XP002390712, DOI: 10.1093/hmg/ddg049 *

Also Published As

Publication number Publication date
SG11201401193XA (en) 2014-05-29
IL231873A0 (en) 2014-05-28
EP2763702A4 (en) 2015-04-15
JP2014531469A (ja) 2014-11-27
TW201321403A (zh) 2013-06-01
CA2850357A1 (en) 2013-04-11
US20150072940A1 (en) 2015-03-12
US20170095530A1 (en) 2017-04-06
EP2763702A1 (en) 2014-08-13
WO2013052507A1 (en) 2013-04-11
RU2014117558A (ru) 2015-11-10
AU2012318736A1 (en) 2014-05-22
US9878006B2 (en) 2018-01-30
BR112014008065A2 (pt) 2019-09-24
IN2014CN03333A (enExample) 2015-07-03
MX2014004029A (es) 2014-08-01
HK1201048A1 (en) 2015-08-21
KR20140108518A (ko) 2014-09-11

Similar Documents

Publication Publication Date Title
US9878006B2 (en) Treatment of obesity and obesity related disorders by pharmalogical targeting of Kv1.3 potassium channels
US12077612B2 (en) Peptide compositions
JP5820349B2 (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
TWI619724B (zh) 新穎之調酸素衍生物及含有該衍生物之用於治療肥胖之醫藥組成物
JP5805632B2 (ja) メラノコルチン受容体に特異的なペプチド
KR101687037B1 (ko) 성기능 장애 치료용 멜라노코르틴 수용체-특이적 펩티드
BR112015001451B1 (pt) Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
JP2008534435A (ja) 膵臓ポリペプチドファミリーモチーフ、ポリペプチドおよびこれらを含む方法
BR112019011859A2 (pt) agonista duplo de glp-1/glp-2, composição, método para aumentar massa intestinal, método de profilaxia ou tratamento de má-absorção intestinal e uso de um agonista duplo
US20090209460A1 (en) Compositions and methods for treating obesity and related metabolic disorders
US20220119473A1 (en) Acylated oxyntomodulin peptide analog
US20200276275A1 (en) Therapies for Obesity, Diabetes and Related Indications
BRPI0615573A2 (pt) análogos de glp-1 estabilizados
WO2014065341A1 (ja) 筋萎縮性側索硬化症治療剤
CN103626866B (zh) 胰多肽家族基序、包含该基序的多肽和方法
US20150197550A1 (en) Therapeutic Uses of Dogfish Glucagon and Analogues Thereof
WO2003066672A1 (fr) Peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1201048

Country of ref document: HK

RJ01 Rejection of invention patent application after publication

Application publication date: 20140813

RJ01 Rejection of invention patent application after publication
REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1201048

Country of ref document: HK